Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$271.75 USD

271.75
1,074,902

+6.98 (2.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $271.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ABMD]

Reports for Purchase

Showing records 221 - 240 ( 286 total )

Industry: Medical - Instruments

Record: 221

10/31/2011

Company Report

Pages: 5

FQ2:2012 Preview: Expect Flat Impella Growth on Seasonality; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 222

08/16/2011

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Instruments

Record: 223

08/15/2011

Daily Note

Pages: 3

Upgrading as stock has reached our PT

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 224

08/15/2011

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 225

08/15/2011

Company Report

Pages: 4

Upgrading as stock has reached our PT

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 226

08/05/2011

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 227

08/04/2011

Company Report

Pages: 8

It?s all about the second half

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 228

08/04/2011

Daily Note

Pages: 3

It?s all about the second half

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 229

08/04/2011

Company Report

Pages: 6

No Major Surprises in FQ1:2012 Results; Continue to Expect Growth Weighted to H2:2012

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 230

08/02/2011

Company Report

Pages: 5

FQ1: 2012 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 231

06/30/2011

Company Report

Pages: 6

Shifting Revenue Growth Towards Second Half of Fiscal 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 232

06/29/2011

Daily Note

Pages: 4

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 233

06/28/2011

Daily Note

Pages: 3

Is the FDA finally waking up?

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 234

06/28/2011

Company Report

Pages: 4

Is the FDA finally waking up?

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 235

05/23/2011

Company Report

Pages: 8

Price: 24.95

Industry: Medical - Instruments

Record: 236

05/19/2011

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 237

05/19/2011

Daily Note

Pages: 3

The reimbursement game continues

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 238

05/19/2011

Company Report

Pages: 7

The reimbursement game continues

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 239

05/18/2011

Company Report

Pages: 7

FY:2012 Guidance Suggests Healthy Growth Will Continue; Raising FV to $22 from $16

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Instruments

Record: 240

05/16/2011

Company Report

Pages: 5

FQ4:2011 Preview; First Revenues Post PROTECT II Data

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 10.00

Research Provided by a Third Party
// eof